inclusion criteria: 1. subject provides written informed consent 2. participant is ≥ 18 and ≤ 65 years of age on the day of signing the icf 3. individuals that are eligible for vaccination according to the austrian vaccination plan. 4. participants that have been vaccinated with either chadox1-s prime within the last 12 weeks or bnt162b2 prime within the last 3 - 6 weeks 5. subject understands and agrees to comply with study procedures 6. subject must be willing to be contacted by telephone or willing to complete an ediary during study participation 7. female participants of childbearing potential may be enrolled in the study if the participant fulfills all the following criteria: * has a negative urine pregnancy test at screening * has agreed to practice adequate contraception from providing consent until 3 months after administration of study vaccine * is not currently breastfeeding adequate female contraception is defined as consistent and correct use of an approved contraceptive method, for example: * barrier method (condoms, diaphragm, cervical cap) used in conjunction with spermicide * prescription hormonal contraceptive taken administered via oral (pill), transdermal (patch), subdermal or im route * intrauterine device * sterilization of a female participant's monogamous male partner prior to study inclusion cave: periodical abstinence (eg calendar, ovulation, symptothermal,...) and withdrawal are not acceptable methods of contraception. 8. female participants of non-childbearing potential may be enrolled in the study. non-childbearing potential is defined as: surgically sterile (history of bilateral dubal ligation, bilateral oophorectomy, hysterectomy) or postmenopausal (amenorrhea for 12 consecutive months prior to screening without an alternative medical cause). 9. participants agrees to not donate bone marrow, blood and blood products from the study vaccine administration until 3 months after receiving the study vaccine

inclusion criteria: 1. subject provides written informed consent 2. participant is ≥ 18 and ≤ 65 years of age on the day of signing the icf 3. individuals that are eligible for vaccination according to the austrian vaccination plan. 4. participants that have been vaccinated with either chadox1-s prime within the last 12 weeks or bnt162b2 prime within the last 3 - 6 weeks 5. subject understands and agrees to comply with study procedures 6. subject must be willing to be contacted by telephone or willing to complete an ediary during study participation 7. female participants of childbearing potential may be enrolled in the study if the participant fulfills all the following criteria: * has a negative urine pregnancy test at screening * has agreed to practice adequate contraception from providing consent until 3 months after administration of study vaccine * is not currently breastfeeding adequate female contraception is defined as consistent and correct use of an approved contraceptive method, for example: * barrier method (condoms, diaphragm, cervical cap) used in conjunction with spermicide * prescription hormonal contraceptive taken administered via oral (pill), transdermal (patch), subdermal or im route * intrauterine device * sterilization of a female participant's monogamous male partner prior to study inclusion cave: periodical abstinence (eg calendar, ovulation, symptothermal,...) and withdrawal are not acceptable methods of contraception. 8. female participants of non-childbearing potential may be enrolled in the study. non-childbearing potential is defined as: surgically sterile (history of bilateral dubal ligation, bilateral oophorectomy, hysterectomy) or postmenopausal (amenorrhea for 12 consecutive months prior to screening without an alternative medical cause). 9. participants agrees to not donate bone marrow, blood and blood products from the study vaccine administration until 3 months after receiving the study vaccine

inclusion criteria: subject provides written informed consent participant is ≥ 18 and ≤ 65 years of age on the day of signing the icf individuals that are eligible for vaccination according to the austrian vaccination plan. participants that have been vaccinated with either chadox1-s prime within the last 12 weeks or bnt162b2 prime within the last 3 - 6 weeks subject understands and agrees to comply with study procedures subject must be willing to be contacted by telephone or willing to complete an ediary during study participation female participants of childbearing potential may be enrolled in the study if the participant fulfills all the following criteria: has a negative urine pregnancy test at screening has agreed to practice adequate contraception from providing consent until 3 months after administration of study vaccine is not currently breastfeeding adequate female contraception is defined as consistent and correct use of an approved contraceptive method, for example: barrier method (condoms, diaphragm, cervical cap) used in conjunction with spermicide prescription hormonal contraceptive taken administered via oral (pill), transdermal (patch), subdermal or im route intrauterine device sterilization of a female participant's monogamous male partner prior to study inclusion cave: periodical abstinence (eg calendar, ovulation, symptothermal,...) and withdrawal are not acceptable methods of contraception. female participants of non-childbearing potential may be enrolled in the study. non-childbearing potential is defined as: surgically sterile (history of bilateral dubal ligation, bilateral oophorectomy, hysterectomy) or postmenopausal (amenorrhea for 12 consecutive months prior to screening without an alternative medical cause). participants agrees to not donate bone marrow, blood and blood products from the study vaccine administration until 3 months after receiving the study vaccine

inclusion criteria: subject provides written informed consent participant is ≥ 18 and ≤ 65 years of age on the day of signing the icf individuals that are eligible for vaccination according to the austrian vaccination plan. participants that have been vaccinated with either chadox1-s prime within the last 12 weeks or bnt162b2 prime within the last 3 - 6 weeks subject understands and agrees to comply with study procedures subject must be willing to be contacted by telephone or willing to complete an ediary during study participation female participants of childbearing potential may be enrolled in the study if the participant fulfills all the following criteria: has a negative urine pregnancy test at screening has agreed to practice adequate contraception from providing consent until 3 months after administration of study vaccine is not currently breastfeeding adequate female contraception is defined as consistent and correct use of an approved contraceptive method, for example: barrier method (condoms, diaphragm, cervical cap) used in conjunction with spermicide prescription hormonal contraceptive taken administered via oral (pill), transdermal (patch), subdermal or im route intrauterine device sterilization of a female participant's monogamous male partner prior to study inclusion cave: periodical abstinence (eg calendar, ovulation, symptothermal,...) and withdrawal are not acceptable methods of contraception. female participants of non-childbearing potential may be enrolled in the study. non-childbearing potential is defined as: surgically sterile (history of bilateral dubal ligation, bilateral oophorectomy, hysterectomy) or postmenopausal (amenorrhea for 12 consecutive months prior to screening without an alternative medical cause). participants agrees to not donate bone marrow, blood and blood products from the study vaccine administration until 3 months after receiving the study vaccine

inclusion criteria: 1. subject provides written informed consent 2. participant is ≥ 18 and ≤ 65 years of age on the day of signing the icf 3. individuals that are eligible for vaccination according to the austrian vaccination plan. 4. participants that have been vaccinated with either chadox1-s prime within the last 12 weeks or bnt162b2 prime within the last 3 - 6 weeks 5. subject understands and agrees to comply with study procedures 6. subject must be willing to be contacted by telephone or willing to complete an ediary during study participation 7. female participants of childbearing potential may be enrolled in the study if the participant fulfills all the following criteria: - has a negative urine pregnancy test at screening - has agreed to practice adequate contraception from providing consent until 3 months after administration of study vaccine - is not currently breastfeeding adequate female contraception is defined as consistent and correct use of an approved contraceptive method, for example: - barrier method (condoms, diaphragm, cervical cap) used in conjunction with spermicide - prescription hormonal contraceptive taken administered via oral (pill), transdermal (patch), subdermal or im route - intrauterine device - sterilization of a female participant's monogamous male partner prior to study inclusion cave: periodical abstinence (eg calendar, ovulation, symptothermal,...) and withdrawal are not acceptable methods of contraception. 8. female participants of non-childbearing potential may be enrolled in the study. non-childbearing potential is defined as: surgically sterile (history of bilateral dubal ligation, bilateral oophorectomy, hysterectomy) or postmenopausal (amenorrhea for 12 consecutive months prior to screening without an alternative medical cause). 9. participants agrees to not donate bone marrow, blood and blood products from the study vaccine administration until 3 months after receiving the study vaccine

inclusion criteria: 1. subject provides written informed consent 2. participant is ≥ 18 and ≤ 65 years of age on the day of signing the icf 3. individuals that are eligible for vaccination according to the austrian vaccination plan. 4. participants that have been vaccinated with either chadox1-s prime within the last 12 weeks or bnt162b2 prime within the last 3 - 6 weeks 5. subject understands and agrees to comply with study procedures 6. subject must be willing to be contacted by telephone or willing to complete an ediary during study participation 7. female participants of childbearing potential may be enrolled in the study if the participant fulfills all the following criteria: - has a negative urine pregnancy test at screening - has agreed to practice adequate contraception from providing consent until 3 months after administration of study vaccine - is not currently breastfeeding adequate female contraception is defined as consistent and correct use of an approved contraceptive method, for example: - barrier method (condoms, diaphragm, cervical cap) used in conjunction with spermicide - prescription hormonal contraceptive taken administered via oral (pill), transdermal (patch), subdermal or im route - intrauterine device - sterilization of a female participant's monogamous male partner prior to study inclusion cave: periodical abstinence (eg calendar, ovulation, symptothermal,...) and withdrawal are not acceptable methods of contraception. 8. female participants of non-childbearing potential may be enrolled in the study. non-childbearing potential is defined as: surgically sterile (history of bilateral dubal ligation, bilateral oophorectomy, hysterectomy) or postmenopausal (amenorrhea for 12 consecutive months prior to screening without an alternative medical cause). 9. participants agrees to not donate bone marrow, blood and blood products from the study vaccine administration until 3 months after receiving the study vaccine